Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies

Reuters

2025/11/11

<a href="https://laohu8.com/S/QNRX">Quoin Pharmaceuticals</a> Achieves Target Rapamycin Loadings in Topical Delivery Technologies

Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582736485"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582736485\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582736485?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582736485","market":"us","top_or_hot":-1,"title":"Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> Achieves Target Rapamycin Loadings in Topical Delivery Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> Achieves Target Rapamycin Loadings in Topical Delivery Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL3QV5M2:1","article_id":"2582736485","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582736485","pubTimestamp":1762867871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QNRX":"Quoin Pharmaceuticals"},"translate_title":"Quoin Pharmaceuticals在局部给药技术中实现了目标雷帕霉素负载量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNRX":0.9},"content_text":"Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies\n    \n\n        Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}